{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-23-000670","form_type":"8-K","ticker":"CMMB","cik":"0001534248","company_name":"Chemomab Therapeutics Ltd.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.473851+00:00","generated_at":"2026-06-19T06:53:12.105053+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Chemomab reports FY2022 net loss of $27.6M; cash runway through March 2024","bullets":["Net loss of $27.6M in 2022 vs $12.5M in 2021; R&D expenses rose 168% to $17.0M.","Cash used in operations was $20.4M; cash, equivalents and deposits fund operations through March 31, 2024.","Phase 2 PSC trial actively recruiting; added 20mg/kg dose arm and open-label extension.","Phase 2 SSc trial planned for H1 2023; completed NASH trial met safety endpoint with encouraging biomarker activity.","No revenue from product sales; accumulated deficit of $64M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-23-000670","json":"https://secwatch.observer/filing/0001178913-23-000670.json","markdown":"https://secwatch.observer/filing/0001178913-23-000670.md","text":"https://secwatch.observer/filing/0001178913-23-000670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/0001178913-23-000670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/zk2329164.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:53:12.105053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f7c065df175d67c77da34190b76a95237126659","claim":"Chemomab Therapeutics Ltd. reported financial results for fiscal year ended December 31, 2022.","evidence_excerpt":"Chemomab Therapeutics Ltd. (“we,” “us,” “our,” or the “Company”) is disclosing its consolidated audited financial statements for the fiscal year ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/0001178913-23-000670-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}